Anti-thrombotic Drug Candidate - EP-7041

Dr. Neil Hayward, co-founder, President, and CEO at eXIthera Pharmaceuticals, Inc., discusses the need for a new anti-thrombotic drug and how eXIthera is addressing that need with their lead product candidate EP-7041. The next step for EP-7041 is Phase 2 clinical trials on cardiac surgery patients.

#Antithrombotic #EP7041 #eXItheraPharmaceuticals

Visit our website

Follow us on our social media channels

Subscribe to our podcast channels

Support us on Patreon

antithrombotic drugs
antithrombotic drugs pharmacology
antithrombotic drugs ppt
antithrombotic drugs mechanism of action
antithrombotic drugs side effects
antithrombotic drugs uses
antithrombotic drugs for stroke
antithrombotic drugs market
antithrombotic drugs indications
antithrombotic drug names
antithrombotic drugs pdf
antithrombotic drugs name
antithrombotic drugs pharmacology and implications for dental practice
antithrombotic medications for stroke
new antithrombotic drugs for stroke prevention
list of antithrombotic drugs for stroke
antithrombotic treatment for ischaemic stroke
antithrombotic drugs examples
antithrombotic medication for stroke prevention
antithrombotic therapy for ischemic stroke
antithrombotic therapy for acute ischemic stroke
antithrombotic and thrombolytic therapy for ischemic stroke
antithrombotic and thrombolytic therapy for ischemic stroke chest
antiplatelet therapy for acute ischaemic stroke
antiplatelet therapy after ischemic stroke or tia
antiplatelet therapy after ischemic stroke
antithrombotic therapy for stroke
antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation
oral antiplatelet therapy for acute ischaemic stroke
oral antiplatelet therapy for acute ischaemic stroke (review)
antiplatelet therapy in acute ischemic stroke
antithrombotic treatment of acute ischemic stroke
anticoagulants versus antiplatelet agents for acute ischaemic stroke
dual antiplatelet therapy after ischemic stroke
antithrombotic therapy for stroke prevention
antithrombotic therapy for stroke prophylaxis
antithrombotic therapy for secondary stroke prevention
antithrombotic therapy after stroke
antithrombotic therapy post stroke
dual antiplatelet therapy in acute ischemic stroke
anticoagulants and antiplatelet agents in acute ischemic stroke
dual antiplatelet therapy in acute transient ischemic attack and minor stroke
dual antiplatelet therapy pretreatment in iv thrombolysis for acute ischemic stroke
antiplatelet therapy in ischemic stroke
antiplatelet for ischemic stroke
antithrombotic treatment of acute ischemic stroke and transient ischemic attack
dual antiplatelet therapy ischemic stroke
dual antiplatelet therapy in ischemic stroke
dapt after ischemic stroke
new opportunities to optimize antithrombotic therapy for secondary stroke prevention
antiplatelet therapy for stroke prevention
antiplatelet therapy for stroke prevention in atrial fibrillation
antiplatelet therapy for secondary stroke prevention
dual antiplatelet therapy for secondary stroke prevention
antithrombotic therapy stroke
antithrombotic therapy in stroke
safety of dual antiplatelet therapy with argatroban in patients with acute ischemic stroke
dual antiplatelet in ischemic stroke
antiplatelet treatment in ischemic stroke treatment
proteinuria predicts resistance to antiplatelet therapy in ischemic stroke
antiplatelet therapy in combination with rtpa thrombolysis in ischemic stroke
antiplatelets in ischemic stroke
antiplatelet drugs for ischemic stroke prevention
antiplatelet after ischemic stroke
antiplatelet agents for secondary prevention of ischemic stroke
antiplatelet for stroke
dual antiplatelet therapy for minor stroke and high-risk transient ischemic attack
ischemic stroke dual antiplatelet therapy
clopidogrel after ischemic stroke
dual antiplatelet therapy for stroke prevention
antiplatelet therapy for preventing stroke in patients with chronic kidney disease
antiplatelet therapy for primary prevention of stroke
antiplatelet therapy for secondary prevention of stroke uptodate
antiplatelet therapy and stroke primary prevention for every diabetic patient
antiplatelet for stroke prevention
antiplatelet agents in secondary stroke prevention selection timing and dose
antiplatelet agents in secondary stroke prevention
dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention
antiplatelet therapy for secondary prevention of stroke
antiplatelet secondary stroke prevention